1. Home
  2. ALLO vs LPRO Comparison

ALLO vs LPRO Comparison

Compare ALLO & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Logo Open Lending Corporation

LPRO

Open Lending Corporation

HOLD

Current Price

$2.12

Market Cap

252.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLO
LPRO
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
252.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ALLO
LPRO
Price
$1.63
$2.12
Analyst Decision
Strong Buy
Buy
Analyst Count
12
7
Target Price
$8.27
$2.83
AVG Volume (30 Days)
4.2M
744.3K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,948,000.00
Revenue This Year
N/A
$306.66
Revenue Next Year
N/A
$7.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.70
52 Week High
$3.78
$6.73

Technical Indicators

Market Signals
Indicator
ALLO
LPRO
Relative Strength Index (RSI) 59.70 67.27
Support Level $1.62 $1.68
Resistance Level $1.88 $2.30
Average True Range (ATR) 0.11 0.14
MACD 0.02 0.06
Stochastic Oscillator 56.41 72.94

Price Performance

Historical Comparison
ALLO
LPRO

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About LPRO Open Lending Corporation

Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.

Share on Social Networks: